Table 1. Patient characteristics (N=132).
| Characteristics | n (%) |
|---|---|
| Gender | |
| Male | 76 (57.58%) |
| Female | 56 (42.42%) |
| Age (years) | |
| Median (range) | 63 (20-82) |
| Duration of disease (days) | |
| Median (range) | 19 (1-3,011) |
| Comorbidity | |
| Yes | 38 (28.79%) |
| No | 94 (71.21%) |
| MDS type | |
| De novo | 127 (96.21%) |
| Secondary | 5 (3.79%) |
| WHO subtype | |
| RCUD | 4 (3.03%) |
| RARS | 3 (2.27%) |
| RCMD | 40 (30.30%) |
| RAEB-1 | 30 (22.73%) |
| RAEB-2 | 36 (27.27%) |
| MDS-U | 6 (4.55%) |
| Del(5q) | 1 (0.76%) |
| CMML-1 | 7 (5.30%) |
| CMML-2 | 4 (3.03%) |
| Unclassified | 1 (0.76%) |
| IPSS risk category | |
| Intermediate-1 | 86 (65.15%) |
| Intermediate-2 | 36 (27.27%) |
| High | 10 (7.58%) |
| ECOG performance status | |
| 0, 1 | 109 (82.58%) |
| ≥2 | 23 (17.42%) |
| Karyotype at baseline | |
| Good | 75 (56.82%) |
| Normal | 69 (52.27%) |
| Other | 6 (4.55%) |
| Intermediate | 27 (20.45%) |
| Poor | 22 (16.67%) |
| Not done | 8 (6.06%) |
CMML, chronic myelomonocytic leukemia; Del, deletion; ECOG, Eastern Cooperative Oncology Group; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; MDS-U, unclassifiable MDS; RAEB, refractory anemia with excess of blasts; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization